Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Arginine deprivation activates immunogenic cell death and enhances anti-tumor immunity in diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

FSFeng ShiShihezi University

Discussion

Loading...

Member takes

Overview

Arginine deprivation therapy induces immunogenic cell death in diffuse large B-cell lymphoma, suggesting enhanced anti-tumor immunity and potential for PD-1 blockade.

Key Points

  • Immunogenic cell death triggered by arginine deprivation therapy enhances anti-tumor immunity in DLBCL.
  • In vitro models exhibited reduced proliferation rates and increased reactive oxygen species with arginine deprivation.
  • Analysis using metabolomics revealed dysregulation of urea cycle metabolites in diffuse large B-cell lymphoma.
  • Study supports the potential benefit of combining arginine deprivation therapy with PD-1 blockade for improved tumor control.

Cite This Study

Feng Shi (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d607https://doi.org/10.1182/blood-2025-3298
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adenosine pathway as a therapeutic target in diffuse large B cell lymphoma2025
  2. 2Damnacanthus giganteus extract block diffuse large b-cell lymphoma proliferation and EMT by regulating mitochondrial dysfunction and glycolysis2025
  3. 3Enhancement of anti-programmed cell death protein-1 immunotherapy in non-small cell lung cancer using arginine and citrulline supplementation2025
  4. 4Metabolic-immune axis in the tumor microenvironment: a new strategy for prognostic assessment and precision therapy in DLBCL and FL2025 · 5 citations
  5. 5Exploiting arginine auxotrophy in Philadelphia-chromosome positive acute lymphoblastic leukemia to deliver personalised metabolomic treatment2025